

# (12) International Application Status Report

**Received at International Bureau:** 21 August 2014 (21.08.2014)

**Information valid as of:** 21 September 2015 (21.09.2015)

**Report generated on:** 01 July 2016 (01.07.2016)

**(10) Publication number:**

WO2015/022447

**(43) Publication date:**

19 February 2015 (19.02.2015)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/FI2014/050620

**(22) Filing Date:**

13 August 2014 (13.08.2014)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

20135832 (FI)

**(31) Priority date(s):**

14 August 2013 (14.08.2013)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

**A61K 38/18** (2006.01); **A61K 38/17** (2006.01); **A61P 7/00** (2006.01); **A61P 7/10** (2006.01)

**(71) Applicant(s):**

LAURANTIS PHARMA OY [FI/FI]; Itäinen Pitkätatu 4 B FI-20520 Turku (FI) *(for all designated states)*

**(72) Inventor(s):**

ALITALO, Kari; c/o Molecular/Cancer Biology Laboratory Biomedicum FI-00014 Helsinki (FI)

JELTSCH, Michael; c/o Molecular/Cancer Biology Laboratory Biomedicum FI-00014 Helsinki (FI)

ANISIMOV, Andrey; c/o Molecular/Cancer Biology Laboratory Biomedicum FI-00014 Helsinki (FI)

**(74) Agent(s):**

KOLSTER OY AB; Iso Roobertinkatu 23 P.O.Box 148 FI-00121 Helsinki (FI)

**(54) Title (EN):** THERAPEUTIC USE OF VEGF-C AND CCBE1

**(54) Title (FR):** UTILISATION THÉRAPEUTIQUE DE VEGF-C ET DE CCBE1

**(57) Abstract:**

**(EN):** The present invention relates to therapeutic methods, us- es and compositions comprising CCBE1 and VEGF-C for treating disorders and conditions involving impaired lym- phatic system, particularly lymphedema.

**(FR):** La présente invention concerne des procédés thérapeutiques, des utilisations et des compositions comprenant CCBE1 et VEGF-C pour traiter des troubles et des états impliquant une déficience du système lymphatique, notamment un lymphœdème.

**International search report:**

Received at International Bureau: 17 November 2014 (17.11.2014) [EP]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Chapter II demand received: 11 June 2015 (11.06.2015)

**(81) Designated States:**

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

**Declarations:**

Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate

Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America